All news

Seven investors report stakes below 5% in Pacira BioSciences (PCRX).

Alpha Vantage · Stock Titan · · AI-summarised by FinFlash

A Schedule 13D amendment for Pacira BioSciences (PCRX) indicates that seven reporting persons, including DOMA Perpetual Capital Management LLC and The John Templeton Foundation, ceased to be beneficial owners of more than 5% of the common shares as of October 8, 2026. Each reporting person now lists 0 shares and 0% beneficial ownership.

Read original source

PCRX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.